New allergy pill shows promise for kids in Long-Term trial
NCT ID NCT01900054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the long-term safety and effectiveness of TAU-284 (bepotastine besilate) in 58 children aged 7 to 15 with perennial allergic rhinitis (year-round nasal allergies). Over 12 weeks, researchers tracked side effects and changes in sneezing, runny nose, and congestion. The goal was to see if the drug is safe and helpful for long-term use in kids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bepotastine besilate (antihistamine tablet)
- What this could lead to
- If successful, this could confirm a safe and effective long-term allergy medication option for children with year-round nasal allergies.
- What could go wrong
- This is a small, completed phase 3 trial with only 58 participants, so results may not apply to all children. As with any drug, side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERENNIAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Reserch site
Kanagawa, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray test could make allergy shots smarter and cheaper
- Dust mite asthma study aims to uncover how dupilumab works inside the body
- New shot could quiet constant sniffles for months
- Scientists hunt for hidden bacteria behind chronic sinusitis
- Can this antihistamine tablet ease Kids' constant stuffy noses?
- New allergy pill shows promise for kids with constant stuffy nose